useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
It is a tripeptide composed of cysteine, glycine, and glutamic acid, and it plays a critical role in neutralising oxidative stress
Other metabolic regulators such as MOTS-c carry their own theoretical considerations in research
This means that sellers of peptides for muscle growth or performance may now face sales bans for those under 18
Instead of targeting only one pathway, it influences several biological processes that together create stronger, thicker, and healthier hair
Finkley et al
